Editorial: Systemic involvement in obstructive sleep apnea: Personalized medicine to improve health outcomes.
作者信息
Labarca Gonzalo, Sanchez-de-la Torre Manuel, Jorquera Jorge
机构信息
Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Precision Medicine in Chronic Diseases, Hospital Universitari Arnau de Vilanova-Santa Maria, IRB Lleida, Faculty of Nursing and Physiotherapy, University of Lleida, Lleida, Spain.
出版信息
Front Med (Lausanne). 2022 Aug 16;9:999977. doi: 10.3389/fmed.2022.999977. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Systemic involvement in obstructive sleep apnea: Personalized medicine to improve health outcomes.社论：阻塞性睡眠呼吸暂停的全身影响：改善健康结局的个性化医疗
Front Med (Lausanne). 2022 Aug 16;9:999977. doi: 10.3389/fmed.2022.999977. eCollection 2022.
2
Personalized Medicine for Obstructive Sleep Apnea Therapies: Are We There Yet?阻塞性睡眠呼吸暂停治疗的个性化医疗：我们做到了吗？
Sleep Med Clin. 2016 Sep;11(3):299-311. doi: 10.1016/j.jsmc.2016.05.003. Epub 2016 Jun 14.
3
Application of Personalized, Predictive, Preventative, and Participatory (P4) Medicine to Obstructive Sleep Apnea. A Roadmap for Improving Care?个性化、预测性、预防性和参与性（P4）医学在阻塞性睡眠呼吸暂停中的应用。改善护理的路线图？
Ann Am Thorac Soc. 2016 Sep;13(9):1456-67. doi: 10.1513/AnnalsATS.201604-235PS.
4
Paradoxical worsening of hypoxemia in a patient treated by noninvasive positive pressure ventilation for obesity hypoventilation syndrome with concomitant obstructive sleep apnea: a case report.肥胖低通气综合征伴阻塞性睡眠呼吸暂停患者接受无创正压通气治疗时出现低氧血症矛盾性加重：一例报告
J Med Case Rep. 2017 Aug 23;11(1):234. doi: 10.1186/s13256-017-1393-1.
5
Matrix metalloproteinases as possible biomarkers of obstructive sleep apnea severity - A systematic review.基质金属蛋白酶作为阻塞性睡眠呼吸暂停严重程度的可能生物标志物——系统评价。
Sleep Med Rev. 2019 Aug;46:9-16. doi: 10.1016/j.smrv.2019.03.010. Epub 2019 Mar 30.
6
Obstructive Sleep Apnea: From Intermittent Hypoxia to Cardiovascular Complications via Blood Platelets.阻塞性睡眠呼吸暂停：从间歇性缺氧通过血小板导致心血管并发症
Front Neurol. 2018 Aug 3;9:635. doi: 10.3389/fneur.2018.00635. eCollection 2018.
7
Further Development of P4 Approach to Obstructive Sleep Apnea.阻塞性睡眠呼吸暂停P4治疗方法的进一步发展
Sleep Med Clin. 2019 Sep;14(3):379-389. doi: 10.1016/j.jsmc.2019.05.004. Epub 2019 Jul 4.
8
Patient-centered care in obstructive sleep apnea: A vision for the future.以患者为中心的阻塞性睡眠呼吸暂停护理：未来愿景。
Sleep Med Rev. 2018 Feb;37:138-147. doi: 10.1016/j.smrv.2017.02.004. Epub 2017 Feb 24.
9
Pericardial Effusion in Obstructive Sleep Apnea without Pulmonary Arterial Hypertension and Daily Hypoxemia - is it Unusual?阻塞性睡眠呼吸暂停无肺动脉高压和每日低氧血症时的心包积液 - 是否罕见？
Balkan Med J. 2018 May 29;35(3):233-237. doi: 10.4274/balkanmedj.2017.0580.
10
Cardiovascular Outcomes and All-Cause Mortality in Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease (Overlap Syndrome).阻塞性睡眠呼吸暂停和慢性阻塞性肺疾病（重叠综合征）患者的心血管结局和全因死亡率。
Ann Am Thorac Soc. 2019 Jan;16(1):71-81. doi: 10.1513/AnnalsATS.201802-136OC.
本文引用的文献
1
Sleep health and the circadian rest-activity pattern four months after COVID-19.新冠感染后四个月的睡眠健康和昼夜节律活动模式。
J Bras Pneumol. 2022 Apr 29;48(3):e20210398. doi: 10.36416/1806-3756/e20210398. eCollection 2022.
2
Obstructive sleep apnea in women: scientific evidence is urgently needed.女性阻塞性睡眠呼吸暂停：迫切需要科学证据。
J Clin Sleep Med. 2022 Jan 1;18(1):1-2. doi: 10.5664/jcsm.9684.
3
Undiagnosed sleep disorder breathing as a risk factor for critical COVID-19 and pulmonary consequences at the midterm follow-up.未确诊的睡眠呼吸障碍作为 COVID-19 重症和中期随访中肺部不良后果的危险因素。
Sleep Med. 2022 Mar;91:196-204. doi: 10.1016/j.sleep.2021.02.029. Epub 2021 Feb 19.
4
Clinical utility of oximetric parameters to identify a high-risk phenotype of moderate-severe Obstructive Sleep Apnea (OSA).氧合参数对识别中重度阻塞性睡眠呼吸暂停（OSA）高危表型的临床应用价值。
Clin Respir J. 2020 Dec;14(12):1166-1175. doi: 10.1111/crj.13256. Epub 2020 Sep 3.
5
A clinic-based cluster analysis in patients with moderate-severe obstructive sleep apnea (OSA) in Chile.智利针对中重度阻塞性睡眠呼吸暂停（OSA）患者的一项基于诊所的聚类分析。
Sleep Med. 2020 Sep;73:16-22. doi: 10.1016/j.sleep.2020.04.001. Epub 2020 Apr 10.
6
Obstructive sleep apnea and nonalcoholic fatty liver disease: do we need to consider this association in current clinical practice?阻塞性睡眠呼吸暂停与非酒精性脂肪性肝病：在当前临床实践中我们是否需要考虑这种关联？
Sleep Med. 2021 Jan;77:355-356. doi: 10.1016/j.sleep.2020.05.016. Epub 2020 May 20.
7
Efficacy of continuous positive airway pressure (CPAP) in the prevention of cardiovascular events in patients with obstructive sleep apnea: Systematic review and meta-analysis.持续气道正压通气（CPAP）预防阻塞性睡眠呼吸暂停患者心血管事件的疗效：系统评价和荟萃分析。
Sleep Med Rev. 2020 Aug;52:101312. doi: 10.1016/j.smrv.2020.101312. Epub 2020 Mar 14.
8
Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial.阻塞性睡眠呼吸暂停及其经持续气道正压通气治疗对急性冠状动脉综合征患者心血管事件发生率的影响（ISAACC 研究）：一项随机对照试验。
Lancet Respir Med. 2020 Apr;8(4):359-367. doi: 10.1016/S2213-2600(19)30271-1. Epub 2019 Dec 12.
9
Chronic intermittent hypoxia in obstructive sleep apnea: a narrative review from pathophysiological pathways to a precision clinical approach.阻塞性睡眠呼吸暂停中的慢性间歇性低氧：从病理生理途径到精准临床方法的叙述性综述。
Sleep Breath. 2020 Jun;24(2):751-760. doi: 10.1007/s11325-019-01967-4. Epub 2019 Nov 22.
10
Differences in patients derived from otolaryngology and other specialties with sleep apnea.耳鼻喉科和其他专科的睡眠呼吸暂停患者的差异。
J Otolaryngol Head Neck Surg. 2019 Oct 22;48(1):53. doi: 10.1186/s40463-019-0373-4.
Zotero 插件